OR WAIT null SECS
Armand Butera is the assistant editor for HCPLive. He attended Fairleigh Dickinson University and graduated with a degree in communications with a concentration in journalism. Prior to graduating, Armand worked as the editor-in-chief of his college newspaper and a radio host for WFDU. He went on to work as a copywriter, freelancer, and human resources assistant before joining HCPLive. In his spare time, he enjoys reading, writing, traveling with his companion and spinning vinyl records. Email him at email@example.com.
A recent press release detailed the phase 3 findings that were presented at the virtual conference, which shows that bimekizumab was well-tolerated and efficacious in patients with moderate to severe plaque psoriasis.
Yesterday, global biopharmaceutical company UCB announced results from BE BRIGHT, an open-label extension study that evaluated the long-term safety, tolerability, and efficacy of bimekizumab.
The study was conducted over 2 years and included adult patients with moderate to severe plaque psoriasis who completed 1 of the trio of phase 3 studies.
Data from the study were presented at the European Academy of Dermatology and Venereology (EADV) 30th Congress.
Earlier data from the BE BRIGHT study open-label extension trial showed that over 8 out of 10 patients with moderate to severe plaque psoriasis who achieved complete skin clearance (PASI 100) at week 16 also maintained PASI 100 responses through to 2 years of treatment with continued dosing.
Overall, the BE BRIGHT study presented at EADV showed that patients who underwent continuous maintenance dosing of bimekizumab achieved sustained levels of skin clearance (PASI 90 and PASI 100) through 2 years.
Those who switched to bimekizumab after 24 weeks of the biologic adalimumab resulted in a sustained increase in PASI 90 and PASI 100 responder rates for the same amount of time.
Additionally, patients who from the BE VIVID study who switched to bimekizumab after 52 weeks of ustekinumab treatment reported a sustained increased in PASI 100 responder rates up to week 100, and those with an inadequate response to the latter showed sustained improvements in levels of skin clearance.
"Following the recent approval of bimekizumab in Europe, we are pleased to share new two-year data at EADV supporting the clinical value of bimekizumab in the treatment of moderate to severe psoriasis,” said Emmanuel Caeymaex, Executive Vice President, Immunology Solutions and Head of U.S., UCB. “The range of longer-term efficacy and safety data presented offer important new insights for the dermatology community and reflect our commitment to improving the standard of care for people with psoriasis.”
An additional analysis that pooled safety data from up to 2 years of treatment in the phase 2 and 3 clinical trials showed the biologic was well tolerated with no new safety signals identified.